BACKGROUND: The ability of supplemental islet infusions (SII) to restore insulin independence in islet transplant recipients with graft dysfunction has been attributed to the coadministration of exenatide. However, improving islet transplant outcomes could explain the success of SII. We aimed to determine the effect on islet graft function and insulin independence of SII using these new protocols, without the use of exenatide. METHODS: Seventeen islet transplant recipients underwent SIIs after developing graft dysfunction requiring insulin use. For induction therapy, four subjects received daclizumab induction therapy, whereas 13 subjects received thymoglobulin and etanercept. Maintenance immunosuppression consisted of sirolimus+tacrolimus or tacrolimus+cellcept. RESULTS: SII was performed 49.3+/-4.8 months (mean+/-SEM) after the preceding islet transplant. Subjects received significantly lower islet mass with their SII compared with initial transplant(s) (6076+/-492 vs. 9071+/-796 IEQ/kg; P=0.003). Fifteen of the 17 subjects (88.2%) became insulin independent 2.4+/-0.5 months after SII. Insulin-independent duration after SII exceeded that of the initial transplant(s) (24.8+/-2.2 vs. 14.2+/-2.6 months by Kaplan-Meier analysis, P=0.009). Subjects show improved glycemic control after SII (HbA1c 7.0%+/-0.2% pre-SII vs. 6.1%+/-0.2% post-SII, P=0.005) and did not become immunosensitized. CONCLUSION: Using current protocols, SII in the absence of exenatide results in impressive insulin-independence rates and the durability of insulin independence seems to be promising. However, a beneficial effect of exenatide should not be discounted until tested in randomized controlled studies.
BACKGROUND: The ability of supplemental islet infusions (SII) to restore insulin independence in islet transplant recipients with graft dysfunction has been attributed to the coadministration of exenatide. However, improving islet transplant outcomes could explain the success of SII. We aimed to determine the effect on islet graft function and insulin independence of SII using these new protocols, without the use of exenatide. METHODS: Seventeen islet transplant recipients underwent SIIs after developing graft dysfunction requiring insulin use. For induction therapy, four subjects received daclizumab induction therapy, whereas 13 subjects received thymoglobulin and etanercept. Maintenance immunosuppression consisted of sirolimus+tacrolimus or tacrolimus+cellcept. RESULTS: SII was performed 49.3+/-4.8 months (mean+/-SEM) after the preceding islet transplant. Subjects received significantly lower islet mass with their SII compared with initial transplant(s) (6076+/-492 vs. 9071+/-796 IEQ/kg; P=0.003). Fifteen of the 17 subjects (88.2%) became insulin independent 2.4+/-0.5 months after SII. Insulin-independent duration after SII exceeded that of the initial transplant(s) (24.8+/-2.2 vs. 14.2+/-2.6 months by Kaplan-Meier analysis, P=0.009). Subjects show improved glycemic control after SII (HbA1c 7.0%+/-0.2% pre-SII vs. 6.1%+/-0.2% post-SII, P=0.005) and did not become immunosensitized. CONCLUSION: Using current protocols, SII in the absence of exenatide results in impressive insulin-independence rates and the durability of insulin independence seems to be promising. However, a beneficial effect of exenatide should not be discounted until tested in randomized controlled studies.
Authors: T Kawahara; T Kin; S Kashkoush; B Gala-Lopez; D L Bigam; N M Kneteman; A Koh; P A Senior; A M J Shapiro Journal: Am J Transplant Date: 2011-08-29 Impact factor: 8.086
Authors: Axel Andres; Scott Livingstone; Tatsuya Kin; Patricia M Campbell; Peter A Senior; Norman M Kneteman; David Bigam; A M James Shapiro Journal: Islets Date: 2015 Impact factor: 2.694
Authors: Meirigeng Qi; Katie Kinzer; Kirstie K Danielson; Joan Martellotto; Barbara Barbaro; Yong Wang; James T Bui; Ron C Gaba; Grace Knuttinen; Raquel Garcia-Roca; Ivo Tzvetanov; Andrew Heitman; Maureen Davis; James J McGarrigle; Enrico Benedetti; Jose Oberholzer Journal: Acta Diabetol Date: 2014-07-18 Impact factor: 4.280
Authors: Cyril P Landstra; Axel Andres; Mikael Chetboun; Caterina Conte; Yvonne Kelly; Thierry Berney; Eelco J P de Koning; Lorenzo Piemonti; Peter G Stock; François Pattou; Marie-Christine Vantyghem; Melena D Bellin; Michael R Rickels Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134
Authors: Zehra Tekin; Marc R Garfinkel; W James Chon; Lindsay Schenck; Karolina Golab; Omid Savari; J Richard Thistlethwaite; Louis H Philipson; Colleen Majewski; Silvana Pannain; Sabarinathan Ramachandran; Kourosh Rezania; Seenu M Hariprasad; J Michael Millis; Piotr Witkowski Journal: Transplant Direct Date: 2016-09-13